@article{5ebc2a15cabc47b280a575f4e2c8186e,
title = "Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma",
abstract = "In Brain Tumor Cooperative Group Study 77-02, eleven institutions randomized 603 adult patients with supratentorial malignant glioma to one of four treatment groups following surgery: conventional radiotherapy (6000 cGy in 30-35 fractions) + BCNU, conventional radiotherapy + streptozotocin, hyperfractionated (twice daily) radiotherapy (6600 cGy in 60 fractions) + BCNU, and conventional radiotherapy with misonidazole followed by BCNU. Data were analyzed for the total randomized population and for the 557 patients (86% with glioblastoma multiforme) who met protocol eligibility specifications (including confirmed histopathology on central review). Median survival was approximately 10 months following randomization. Overall there was no statistically significant difference in survival among the four groups. Among non-glioblastoma patients, the misonidazole group appeared to have poor survival. Peripheral neuropathy was a dose-limiting toxicity with misonidazole. It is concluded that neither the addition of misonidazole nor hyperfractionated radiotherapy as given in this protocol offered any advantage over conventional radiotherapy plus either BCNU or streptozotocin for treatment of malignant glioma.",
keywords = "Chemotherapy, Glioblastoma multiforme, Hyperfractionation, Malignant glioma, Radiosensitizers, Radiotherapy",
author = "Melvin Deutsch and Green, {Sylvan B.} and Strike, {Thomas A.} and Burger, {Peter C.} and Robertson, {James T.} and Selker, {Robert G.} and Shapiro, {William R.} and John Mealey and Joseph Ransohoff and Pietro Paoletti and Smith, {Kenneth R.} and Odom, {Guy L.} and Hunt, {William E.} and Byron Young and Eben Alexander and Walker, {Michael D.} and Pistenmaa, {David A.}",
note = "Funding Information: Preliminary results presented in part at the Annual Meeting of the American Society of Clinical Oncology, Toronto, Ontario, Canada, May 6-8, 1984. Reprint requests to: Sylvan B. Green, M.D., Clinical and Diagnostic Trials Section, Biometry Branch, Executive Plaza North, Rm 344, NCI, Bethesda, MD 20892. AcknoMll~d~ements-The authors acknowledge the important contributions of Maureen Volz, National Cancer Institute, and Marie Topor, Julie Buckland. Susan Holmes, and Lauren Rich, Information Management Services, Inc., for data collection and processing; and Julie Paolella for typing the manuscript. This investigation was carried out by the members of the Brain Tumor Study Group, in part under contract with the National Cancer Institute, National Institutes of Health, Department of Health and Human Services. The institutions, principal investigators, and contributing investigators in this study were: Bowman Gray School of Medicine, Contract No. NOI-CM-67054, Eben Alexander, Jr., M.D., and Milton Raben, M.D.; Duke University Medical Center, Contract No. NO 1 -CM-670 IO, Peter C. Burger, M.D., and Guy L. Odom, M.D.; Indiana University School of Medicine, Contract No. NOI-CM-67057, John Mealey, Jr., series of randomized clinical trials investigating various multimodality treatment regimens for malignant gliomas.",
year = "1989",
month = jun,
doi = "10.1016/0360-3016(89)90939-5",
language = "English (US)",
volume = "16",
pages = "1389--1396",
journal = "International journal of radiation oncology, biology, physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "6",
}